ICSI treatment linked to increased prostate cancer risk

Men who undergo ICSI (intracytoplasmic sperm injection) are at greater risk of developing prostate cancer, according to a large study presented during the European Society of Human Reproduction and Embryology annual meeting.Medical Xpress
Source: Society for Endocrinology - Category: Endocrinology Source Type: news

Related Links:

Conclusion: The increases in the incidence of different types of cancer in the past decade could be due to the revolutionary change in socioeconomic status that has occurred in Saudi Arabia; therefore, a national plan should be established for cancer prevention, screening and therapy. Concerning mortality, the decrease in its percentage among elderly people could be due to biological factors that should be investigated in the future. PMID: 30520511 [PubMed - in process]
Source: Saudi Medical Journal - Category: Middle East Health Tags: Saudi Med J Source Type: research
Publication date: Available online 8 December 2018Source: European UrologyAuthor(s): Tommy Nyberg, Koveela Govindasami, Goska Leslie, Tokhir Dadaev, Elizabeth Bancroft, Holly Ni Raghallaigh, Mark N. Brook, Nafisa Hussain, Diana Keating, Andrew Lee, Romayne McMahon, Angela Morgan, Andrea Mullen, Andrea Osborne, Reshma Rageevakumar, The UK Genetic Prostate Cancer Study Collaborators, Zsofia Kote-Jarai, Rosalind Eeles, Antonis C. AntoniouAbstractBackgroundThe homeobox B13 (HOXB13) G84E mutation has been recommended for use in genetic counselling for prostate cancer (PCa), but the magnitude of PCa risk conferred by this mutati...
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionsThe Y-chromosomal lncRNA TTTY15 was upregulated in most PCa tissues and could promote PCa progression by sponging let-7.Patient summaryWe found that TTTY15 levels were frequently elevated in prostate cancer (PCa) tissues compared with those in paracancerous normal tissues in a large group of PCa patients, and we observed a tumour suppressive effect after TTTY15 knockout using CRISPR/Cas9. These results may have therapeutic implications for PCa patients.
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conclusions The clinical implementation of the standardized care pathway is described as a straight path through care, but patients described their experiences as walking a tightrope. Lack of information, especially about cancer treatment and its adverse effects, was the most common experience. Implications for Practice Our findings indicate areas where further healthcare tools could improve patient experiences of cancer treatment. This could include offering individualized information and tools to increase patient empowerment, as well as patient/caregiver collaboration (co-care).
Source: Cancer Nursing - Category: Nursing Tags: ARTICLES: ONLINE ONLY Source Type: research
In conclusion, ICA-1s is stable, shows low toxicity, and is a potential therapeutic for prostate carcinoma tumors.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: PRECLINICAL REPORTS Source Type: research
AbstractOral enzalutamide (Xtandi®), a second generation androgen receptor inhibitor, is indicated for the treatment of castration-resistant prostate cancer (CRPC) in numerous countries worldwide, with specific indications in this patient population varying between individual countries. Based on extensive experience in the clinical trial and/or real-world settings, oral enzalutamide 160 mg once daily is an effective and generally well tolerated treatment in a broad spectrum of patients with CRPC, including in nonmetastatic and metastatic disease and in chemotherapy-naive and -experienced metastatic CRPC. Enzalutamide i...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Condition:   Prostate Cancer Intervention:   Drug: Ga-68 PSMA11 Sponsor:   Mayo Clinic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion Positive 11C-choline PET/CT result had an important effect in the therapeutic management of patients with PCa and BR, leading to a change in the planned approach in two (66.1%) out of three patients. In addition, in 4.5% of the patients, the 11C-choline PET/CT allowed the detection of a second malignancy.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: ORIGINAL ARTICLES Source Type: research
Purpose The intensity of prostate-specific membrane antigen (PSMA) expression increases as the tumor grade increases and the uptake of Ga-68-PSMA is higher in high-grade tumors. The aim of the present study was to evaluate the correlation of preoperative tracer uptake of primary tumor to Gleason Score in patients who underwent prostatectomy. Patients and methods We retrospectively evaluated 141 patients who had Ga-68-PSMA positron emission tomography/computed tomography (PET/CT) imaging and who underwent prostatectomy. All patients had a diagnosis of prostate cancer on the basis of 10–24 cores transrectal ultras...
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: ORIGINAL ARTICLES Source Type: research
Zhengming Wang, Yingying Wang, Shan Zhu, Yao Liu, Xin Peng, Shaolu Zhang, Zhe Zhang, Yuling Qiu, Meihua Jin, Ran Wang, Yuxu Zhong, Dexin Kong
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Endocrinology | ICSI (Intracytoplasmic Sperm Injection) | Prostate Cancer | Reproduction Medicine | Study